Cladribine Tablets Reduce Treatment Switches, Outpatient Visits, and Health Care Costs in Multiple Sclerosis | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

February 7, 2026 - 18:27

A recent real-world study has provided compelling evidence for the effectiveness of cladribine tablets in treating multiple sclerosis (MS). The research indicates that patients initiating treatment with oral cladribine exhibited significantly greater treatment persistence compared to those starting other commonly used disease-modifying therapies.

The findings highlight a substantial clinical and economic impact. Notably, patients on cladribine were far less likely to switch medications, suggesting better tolerability and efficacy in a real-world setting. This increased treatment adherence translated into tangible healthcare benefits. The study documented a marked reduction in the need for outpatient visits, alleviating burden on both patients and clinical resources.

Furthermore, the analysis revealed a significant reduction in overall healthcare costs associated with cladribine use. The combination of fewer treatment switches, decreased outpatient utilization, and sustained disease management contributed to these lower costs. This data strengthens the position of cladribine tablets as a valuable treatment option, offering a high-efficacy therapy that can promote treatment stability and reduce the economic burden of MS care. The study underscores the importance of selecting an effective initial therapy to improve long-term patient outcomes and healthcare resource allocation.